» Articles » PMID: 24566902

Prevalence of Age-related Macular Degeneration in a Large European Cohort: Results from the Population-based Gutenberg Health Study

Overview
Specialty Ophthalmology
Date 2014 Feb 26
PMID 24566902
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of this study was to describe the sex- and age-specific prevalence of age-related macular degeneration (AMD) and its correlation with urban or rural residence in a large and relatively young European cohort.

Methods: We evaluated fundus photographs from participants in the Gutenberg Health Study (GHS), a population-based, prospective, observational, single-centre study in the Rhineland-Palatine region in midwestern Germany. The participants were 35-74 years of age at enrolment. The fundus images were classified as described in the Rotterdam Study and were graded independently by two experienced ophthalmologists (CK and UBK) based on the presence of hard and soft drusen, retinal pigmentary abnormalities, and signs of atrophic or neovascular age-related macular generation (AMD).

Results: Photographs from 4,340 participants were available for grading. Small, hard drusen (<63 μm, stages 0b and 0c) were present in 37.4% of participants (95% confidence interval [CI], stage 0b, 31.6% [30.3-33.7]; stage 0c, 5.8% [5.1-6.5]). Early AMD (soft drusen, pigmentary abnormalities, stages 1-3) was present in 3.8% of individuals in the youngest age group (35-44 years) (95% CI, stage 1a, 0.4% [0.3-0.5%]; stage 1b, 3.2% [2.9-3.5%]; stage 2a, 0.1% [0.1-0.2%]; stage 2b, 0% [0-0.0%]; stage 3, 0.1% [0.1-0.2%]), whereas late AMD (stages 4a and 4b) did not appear in the youngest age group. In all age groups, signs of early AMD were detected in 11.9% of individuals (stage 1a, 2.1% [1.7-2.6]; stage 1b, 8.0% [7.2-8.8]; stage 2a, 1.0% [0.7-1.3]; stage 2b, 0.5% [0.3-0.7]; stage 3, 0.3% [0.2-0.6]). Late AMD (geographic atrophy or neovascular AMD) was found in 0.2% of individuals (stage 4a, 0.1 % [0.0-0.2]; stage 4b, 0.1% [0.0-0.2]). AMD increased significantly with age (odds ratio [OR], 1.09; 95% CI, 1.08-1.10). Sex, iris colour, and residence (rural vs. urban) were not associated with different rates of AMD.

Conclusions: In this study, the prevalence of AMD increased dramatically with age; however, although AMD is usually thought to occur after age 50, signs of early AMD were found in 3.8% of individuals in the youngest age group (younger than 45 years). This population-based sample is the first to provide substantial epidemiologic data from a large German cohort, including data on macular degeneration in younger age groups and incidence data after recall.

Citing Articles

Rheumatic fever and long-term use of benzathine penicillin as possible risk factors for extensive macular atrophy with pseudodrusen in a Brazilian cohort.

Moreira-Neto C, Schmidt Andujar R, Chao J, Vasconcelos H, Alves F, Rodrigues G Int J Retina Vitreous. 2024; 10(1):75.

PMID: 39394154 PMC: 11468192. DOI: 10.1186/s40942-024-00592-y.


(rs1061170, rs1410996), (rs2071559, rs1870377) and KDR and CFH Serum Levels in AMD Development and Treatment Efficacy.

Cebatoriene D, Vilkeviciute A, Gedvilaite G, Bruzaite A, Kriauciuniene L, Zaliuniene D Biomedicines. 2024; 12(5).

PMID: 38790910 PMC: 11117782. DOI: 10.3390/biomedicines12050948.


Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data.

Schuster A, Leisle L, Picker N, Bubendorfer-Vorwerk H, Lewis P, Hahn P Ophthalmol Ther. 2024; 13(4):1025-1039.

PMID: 38386186 PMC: 10912065. DOI: 10.1007/s40123-024-00901-6.


Systemic Evidence for Mitochondrial Dysfunction in Age-Related Macular Degeneration as Revealed by mtDNA Copy Number Measurements in Peripheral Blood.

Koller A, Lamina C, Brandl C, Zimmermann M, Stark K, Weissensteiner H Int J Mol Sci. 2023; 24(22).

PMID: 38003595 PMC: 10671207. DOI: 10.3390/ijms242216406.


[Inherited retinal diseases in Germany-Challenges in health care supply structure and diagnostics].

Bolz H, Kochs C, Holz F, Bucher F, Herrmann P Ophthalmologie. 2023; 120(12):1251-1257.

PMID: 37606831 DOI: 10.1007/s00347-023-01903-8.


References
1.
Buch H, Nielsen N, Vinding T, Jensen G, Prause J, La Cour M . 14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. Ophthalmology. 2005; 112(5):787-98. DOI: 10.1016/j.ophtha.2004.11.040. View

2.
Hyman L, LILIENFELD A, Ferris 3rd F, Fine S . Senile macular degeneration: a case-control study. Am J Epidemiol. 1983; 118(2):213-27. DOI: 10.1093/oxfordjournals.aje.a113629. View

3.
Klein R, Clegg L, Cooper L, Hubbard L, Klein B, King W . Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol. 1999; 117(9):1203-10. DOI: 10.1001/archopht.117.9.1203. View

4.
Hoehn R, Mirshahi A, Hoffmann E, Kottler U, Wild P, Laubert-Reh D . Distribution of intraocular pressure and its association with ocular features and cardiovascular risk factors: the Gutenberg Health Study. Ophthalmology. 2013; 120(5):961-8. DOI: 10.1016/j.ophtha.2012.10.031. View

5.
Lim L, Mitchell P, Seddon J, Holz F, Wong T . Age-related macular degeneration. Lancet. 2012; 379(9827):1728-38. DOI: 10.1016/S0140-6736(12)60282-7. View